| Not Yet Recruiting | Clonal Hematopoiesis of Immunological Significance NCT05969821 | Assistance Publique - Hôpitaux de Paris | — |
| Not Yet Recruiting | DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Y NCT07440290 | Cancer Research UK | Phase 2 / Phase 3 |
| Recruiting | DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Paediatric and Teenage/Young Adult Patients With ROS1 NCT05770544 | Cancer Research UK | Phase 2 / Phase 3 |
| Recruiting | A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma NCT07075185 | Kelonia Therapeutics, Inc. | Phase 1 |
| Recruiting | Feasibility of a Multi-omics Platform for Hematological Malignancies NCT07445438 | Azienda Ospedaliero-Universitaria di Parma | N/A |
| Withdrawn | Preemptive Infusion of Donor Lymphocytes Depleted of TCR + T Cells + CD19+ B Cells Following ASCT NCT03939585 | Leland Metheny | Phase 1 |
| Not Yet Recruiting | Familial B-cell Lymphoproliferative Disorders NCT05718986 | University of Haifa | — |
| Recruiting | A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study NCT06271252 | OriCell Therapeutics Co., Ltd. | Phase 1 |
| Recruiting | DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Pos NCT05770037 | Cancer Research UK | Phase 2 / Phase 3 |
| Recruiting | DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Canc NCT05770102 | Cancer Research UK | Phase 2 / Phase 3 |
| Recruiting | Virtual Rehabilitation for Cancer Survivors NCT05898789 | University Health Network, Toronto | N/A |
| Recruiting | Pacritinib in Relapsed/Refractory T-cell Lymphoproliferative Neoplasms NCT04858256 | University of Michigan Rogel Cancer Center | Phase 2 |
| Withdrawn | A Study of Zilovertamab and Ibrutinib in Patients With Relapsed or Refractory Mantle Cell Lymphoma NCT05431179 | Oncternal Therapeutics, Inc | Phase 3 |
| Unknown | CAR-NK Cells Production and Expansion From Patients With Lympho or Myeloproliferative Disorders and From Healt NCT06727383 | European Institute of Oncology | N/A |
| Unknown | Liquid Biopsy to Enable Diagnostics and Monitoring for Immune-mediated Lymphoproliferative Disorders NCT05803616 | University Hospital, Geneva | — |
| Completed | Trial of Written Exposure for Metastatic Cancer Patients (EASE) NCT06042400 | University of Colorado, Boulder | N/A |
| Unknown | In Vitro Drug Sensitivity Testing of Fresh Human Samples NCT05001386 | Hospices Civils de Lyon | N/A |
| Unknown | Study to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) M NCT05155215 | Beijing Immunochina Medical Science & Technology Co., Ltd. | Phase 1 / Phase 2 |
| Recruiting | Chemogenomic Profiling in Hematological Malignancies (HEM-Profiling 2021) NCT07445984 | Azienda Ospedaliero-Universitaria di Parma | N/A |
| Recruiting | A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases NCT04554914 | Pierre Fabre Medicament | Phase 2 |
| Unknown | Expression of CD19 Complex in Lymphoproliferative Disorders NCT04734470 | Assiut University | — |
| Recruiting | Allogeneic Hematopoietic Stem Cell Transplant for Patients With Inborn Errors of Immunity NCT04339777 | National Cancer Institute (NCI) | Phase 2 |
| Unknown | Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma NCT04309084 | Celularity Incorporated | Phase 1 |
| Terminated | Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders NCT03601819 | University of Michigan Rogel Cancer Center | Phase 1 |
| Recruiting | Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma NCT03922724 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL NCT03602157 | UNC Lineberger Comprehensive Cancer Center | Phase 1 |
| Completed | A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymp NCT03744676 | Juno Therapeutics, a Subsidiary of Celgene | Phase 2 |
| Active Not Recruiting | Allogeneic Hematopoietic Cell Transplantation for Disorders of T-cell Proliferation and/or Dysregulation NCT03663933 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Dose Escalation & Expansion Study of Oral VRx-3996 & Valganciclovir in Subjects With EBV+ Lymphoid Malignancie NCT03397706 | Viracta Therapeutics, Inc. | Phase 1 / Phase 2 |
| Recruiting | A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphopro NCT03394365 | Pierre Fabre Medicament | Phase 3 |
| Unknown | Chidamide Combined With R-GDP in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma ( NCT03373019 | Fudan University | Phase 2 |
| Unknown | Mechanisms of Action of Photo(Chemo)Therapy in Skin Diseases NCT03340155 | Medical University of Graz | N/A |
| Active Not Recruiting | Study of CD30 CAR for Relapsed/Refractory CD30+ HL and CD30+ NHL NCT02690545 | UNC Lineberger Comprehensive Cancer Center | Phase 1 / Phase 2 |
| Active Not Recruiting | Administration of T Lymphocytes for Prevention of Relapse of Lymphomas NCT02663297 | UNC Lineberger Comprehensive Cancer Center | Phase 1 |
| Completed | Nivolumab With Epstein Barr Virus Specific T Cells (EBVSTS), Relapsed/Refractory EBV Positive Lymphoma (PREVAL NCT02973113 | Baylor College of Medicine | Phase 1 |
| Recruiting | Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies NCT02579967 | National Cancer Institute (NCI) | Phase 2 |
| Unknown | Transfusion-related EBV Infection Among Allogeneic Stem Cell Transplant Pediatric Recipients NCT02505789 | St. Justine's Hospital | — |
| Withdrawn | Study of Phenethyl Isothiocyanate in Lymphoproliferative Disorders NCT00968461 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Plerixafor Harvesting And No Chemotherapy for Transplantation of Autologous STem Cells In Cancer (PHANTASTIC) NCT01186224 | University of Liverpool | N/A |
| Terminated | Study of HQK-1004 and Valganciclovir to Treat Epstein-Barr Virus (EBV) - Positive Lymphoid Malignancies or Lym NCT00992732 | HemaQuest Pharmaceuticals Inc. | Phase 2 |
| Enrolling By Invitation | Pathogenesis of Hematologic Malignancies NCT01728402 | OHSU Knight Cancer Institute | — |
| Terminated | Reduced Intensity Preparative Regimen Followed by Stem Cell Transplant (FAB) NCT00579111 | Baylor College of Medicine | Phase 1 / Phase 2 |
| Recruiting | Establishing a Tumor Bank in Families With Multiple Lymphoproliferative Malignancies NCT00131014 | Dana-Farber Cancer Institute | — |
| Terminated | Trial of MEDI-507 in CD2-Positive Lymphoproliferative Disease NCT00123942 | MedImmune LLC | Phase 1 |
| Completed | Fluorodeoxyglucose-Positron Emission Tomography (FDG-PET) to Evaluate Autoimmune Lymphoproliferative Syndrome NCT00068146 | National Institute of Allergy and Infectious Diseases (NIAID) | — |
| Completed | Detection and Cytotoxic T Lymphocyte Therapy of Post-Transplant Lymphoproliferative Disorder After Liver Trans NCT00063648 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Phase 1 |
| Completed | Prevention and Treatment of Epstein-Barr Virus (EBV) Lymphoma Following a Solid Organ Transplant Using EBV Spe NCT00058604 | Baylor College of Medicine | Phase 1 |
| Completed | Stem Cell Transplant for Patients With Blood Malignancy Using Donors and Less Toxic Chemotherapy With CAMPATH NCT00048412 | Baylor College of Medicine | Phase 1 / Phase 2 |
| Completed | Clofarabine in Chronic Lymphocytic Leukemia NCT00028418 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | A Pilot Study of the Combination of Retinoic Acid and Interferon-Alpha2a for the Treatment of Lymphoproliferat NCT00001438 | National Cancer Institute (NCI) | Phase 2 |
| No Longer Available | Expanded Access Protocol for Tabelecleucel for Patients With Epstein-Barr Virus-Associated Viremia or Malignan NCT02822495 | Atara Biotherapeutics | — |
| Completed | Topical Use of 4,4'-Dihydroxybenzophenone-2,4-Dinitrophenylhydrazone (A-007) in the Treatment of Advanced Mali NCT00002153 | DEKK-TEC, Inc. | Phase 1 |